Novo har sagsøgt Eli Lilly for markedsføring af vægttabsmedicin, som de betragter som vildledende. I reklamen sammenligner Lilly Zepbound med en ældre og mildere dosis af Wegovy, selvom Novo allerede har en nyere og mere effektiv version. Lilly understreger selv, at deres sammenligning er baseret på den eneste direkte undersøgelse.
Key Points
- Novo Nordisk CEO Mike Doustdar defended the drugmaker’s decision to sue rival Eli Lilly over its weight-loss drug advertising.
- “I am a big fan of competition. I think competition has to be fierce, but I also think competition has to be fair,” Doustdar said on CNBC’s “Mad Money.” “I believe that patients deserve to know the full truth together with their physicians before they make a choice of what product to take.”
https://www.cnbc.com/2026/08/12/novo-nordisk-ceo-defends-lawsuit-against-eli-lilly.html